Global Neurotrophic Keratitis Market is valued approximately USD 92 million in 2019 and is anticipated to grow with a healthy growth rate of more than 17% over the forecast period 2019-2026. Neurotrophic Keratitis (NK) is a neurodegenerative disease caused by the injury of trigeminal nerve that affects the cornea of an eye. In this disease, the patient drops the corneal sensitivity and thus cornea is unprotected to damages without treatment. If this disease is not treated and diagnosed properly, the patient can loss permanent eye vision. The treatment of neurotrophic keratitis is done by a team that includes neurologists, ophthalmologists and corneal specialists. Treatments are available based on the severity of the disease. Neurotrophic Keratitis treatment comprises topical antibiotics, bandage contact lenses, preservative artificial tears, amniotic membrane transplantation, keratoplasty, Recombinant human nerve growth factor (rhNGF), and so on. Growing number of approvals for new product innovation from regulatory authorities, with the huge financial support to the researchers for developing novel treatments are the few factors responsible for high CAGR of the market over the forecast period. For instance, in August 2018, Dompe farmaceutici S.p.A. has received approval for cenegermin topical eyes drop from FDA, which is a recombinant human nerve growth factor for the therapy of neurotrophic keratitis. The cenegermin has also obtained an Orphan Drug designation, Breakthrough Therapy designation and Fast Track status from the FDA. This, in turn, is expected to accelerate the growth of Neurotrophic Keratitis market around the world. However, low healthcare budget in some of the developing countries is one of the major factors expected to hamper the growth of the market over the forecast period of 2020-2026.

The regional analysis of global Neurotrophic Keratitis market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the rising product approvals, presence of well-established healthcare infrastructure, and increase in R&D activities in neurotrophic keratitis in the region. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2026, due to growing geriatric population and increasing government investments in healthcare and R&D present in the countries like China and India.

Major market player included in this report are:
Allergan, Plc.
Abbott Laboratories, Inc.
Bausch & Lomb Incorporated
Bayer AG
CooperVision
Dompe farmaceutici S.p.A.
Johnson & Johnson
Novartis AG
ReGenTree, LLC.
Walgreens

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Treatment Type:
Preservative Free Artificial Tears
Topical Antibiotics
Amniotic Membrane Transplantation
Tarsorrhaphy
Recombinant Human Nerve Growth Factor (rhNGF)
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017, 2018
Base year – 2019
Forecast period – 2020 to 2026

Target Audience of the Global Neurotrophic Keratitis Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors